Ventus is a newly established venture-backed biotech company pursuing small molecule therapeutics targeting key innate immune pathways for numerous auto-immune and auto-inflammatory diseases. Ventus was founded by world leaders in structural immunology and innate immunity who discovered that innate immune signaling leads to the formation of multimeric complexes that drive the subsequent inflammatory cascade. Leveraging the expertise of our founders, Ventus is the only company capable of pursuing biochemical and structure-based drug discovery for highly sought-after targets of these multimeric complexes.